IP Library Granted Patent US 10,961,522
Granted Patent B2
US 10,961,522 · App. 16/252,505 · Granted Mar 30, 2021

Highly potent acid alpha-glucosidase with enhanced carbohydrates

Inventors: Russell Gotschall (Doylestown, PA); Hung V. Do (New Hope, PA)
Assignee: Amicus Therapeutics, Inc.
C12N9/2465A61K48/005C12N15/09C12Y302/0102C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,961,522
App. No.
16/252,505
Granted
Mar 30, 2021
Kind
B2
Abstract

Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.

Claims (14)

1. A method for modulating lysosomal proliferation or autophagy in a cell comprising administering to a subject a composition comprising recombinant human acid alpha-glucosidase (rhGAA) produced from Chinese hamster ovary (CHO) cells, wherein 40%-60% of the N-glycans on the rhGAA are complex type N-glycans and the rhGAA comprises 3.0-5.0 mol mannose-6-phosphate (M6P) residues per mol rhGAA.

2. The method of claim 1 , wherein the rhGAA comprises 3.0 to 4.0 mol M6P per mol rhGAA.

3. The method of claim 1 , wherein the rhGAA comprises 4.0 to 5.0 mol M6P per mol rhGAA.

4. The method of claim 1 , wherein about 45%-55% of the N-glycans on the rhGAA are complex type N-glycans.

5. The method of claim 1 , wherein 50% of the N-glycans on the rhGAA are complex type N-glycans.

6. The method of claim 1 , wherein the rhGAA comprises at least one bis-phosphorylated N-glycan per rhGAA.

7. The method of claim 1 , wherein the rhGAA further comprises

(a) 2.0 to 8.0 mol sialic acid per mol rhGAA; or

(b) at least 4 mol sialic acid per mol rhGAA.

8. The method of claim 1 , wherein the method further comprises administering a pharmacological chaperone, and wherein said composition and said pharmacological chaperone are either administered as a single pharmaceutical composition or administered separately.

9. The method of claim 8 , wherein the pharmacological chaperone is N-butyl-deoxynojirimycin or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the rhGAA is conjugated to a targeting moiety.

11. The method of claim 1 , wherein the method modulates lysosomal proliferation.

12. The method of claim 1 , wherein the method modulates autophagy.

Assignments (5)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: HAYFIN SERVICES LLP
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 065164/0945 →
SECURITY INTEREST Recorded Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →
SECURITY INTEREST Recorded Jul 30, 2020
From: AMICUS THERAPEUTICS, INC.
To: HAYFIN SERVICES LLP, AS AGENT
Reel/Frame 053365/0342 →
Continuity (6)
Continuation 15515808
Provisional Application 62057842 · Sep 30, 2014
Provisional Application 62057847 · Sep 30, 2014
Provisional Application 62112463 · Feb 5, 2015
Provisional Application 62135345 · Mar 19, 2015
Related Publication 20190276812A1 · Sep 12, 2019
Cited By (7)
US 12,246,062 US 12,325,753 US 12,414,985 US 12,428,487 US 12,622,952 US 12,662,545 US 12,686,859